AnGes, Inc. has entered a collaboration agreement with Brickell Biotech, Inc., a clinical-stage pharmaceutical company, under which Brickell has the right to develop AnGes’ investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets.
>>2819
同意します。
AnGes, Inc. has entered a collaboration agreement with Brickell Biotech, Inc., a clinical-stage pharmaceutical company, under which Brickell has the right to develop AnGes’ investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets.